196 related articles for article (PubMed ID: 18697940)
1. Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray.
Kawamata N; Ogawa S; Zimmermann M; Niebuhr B; Stocking C; Sanada M; Hemminki K; Yamatomo G; Nannya Y; Koehler R; Flohr T; Miller CW; Harbott J; Ludwig WD; Stanulla M; Schrappe M; Bartram CR; Koeffler HP
Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11921-6. PubMed ID: 18697940
[TBL] [Abstract][Full Text] [Related]
2. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer.
An Q; Wright SL; Konn ZJ; Matheson E; Minto L; Moorman AV; Parker H; Griffiths M; Ross FM; Davies T; Hall AG; Harrison CJ; Irving JA; Strefford JC
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17050-4. PubMed ID: 18957548
[TBL] [Abstract][Full Text] [Related]
3. Dominant-negative mechanism of leukemogenic PAX5 fusions.
Kawamata N; Pennella MA; Woo JL; Berk AJ; Koeffler HP
Oncogene; 2012 Feb; 31(8):966-77. PubMed ID: 21765475
[TBL] [Abstract][Full Text] [Related]
4. FOXP1 and PAX5 are rare but recurrent translocations partners in acute lymphoblastic leukemia.
Put N; Deeren D; Michaux L; Vandenberghe P
Cancer Genet; 2011 Aug; 204(8):462-4. PubMed ID: 21962897
[TBL] [Abstract][Full Text] [Related]
5. PAX5 fusion genes in acute lymphoblastic leukemia: A literature review.
Fouad FM; Eid JI
Medicine (Baltimore); 2023 May; 102(20):e33836. PubMed ID: 37335685
[TBL] [Abstract][Full Text] [Related]
6. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
Bousquet M; Broccardo C; Quelen C; Meggetto F; Kuhlein E; Delsol G; Dastugue N; Brousset P
Blood; 2007 Apr; 109(8):3417-23. PubMed ID: 17179230
[TBL] [Abstract][Full Text] [Related]
7. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia.
Nebral K; König M; Harder L; Siebert R; Haas OA; Strehl S
Br J Haematol; 2007 Oct; 139(2):269-74. PubMed ID: 17897302
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient.
Kanayama T; Imamura T; Mayumi A; Soma E; Sakamoto K; Hayakawa F; Tanizawa A; Kiyokawa N; Hosoi H
Int J Hematol; 2020 Nov; 112(5):714-719. PubMed ID: 32656633
[TBL] [Abstract][Full Text] [Related]
9. Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study.
Coyaud E; Struski S; Prade N; Familiades J; Eichner R; Quelen C; Bousquet M; Mugneret F; Talmant P; Pages MP; Lefebvre C; Penther D; Lippert E; Nadal N; Taviaux S; Poppe B; Luquet I; Baranger L; Eclache V; Radford I; Barin C; Mozziconacci MJ; Lafage-Pochitaloff M; Antoine-Poirel H; Charrin C; Perot C; Terre C; Brousset P; Dastugue N; Broccardo C
Blood; 2010 Apr; 115(15):3089-97. PubMed ID: 20160164
[TBL] [Abstract][Full Text] [Related]
10. Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development.
Fortschegger K; Anderl S; Denk D; Strehl S
Mol Cancer Res; 2014 Apr; 12(4):595-606. PubMed ID: 24435167
[TBL] [Abstract][Full Text] [Related]
11. The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia.
Qiu JJ; Chu H; Lu X; Jiang X; Dong S
Oncogene; 2011 Feb; 30(8):967-77. PubMed ID: 20972455
[TBL] [Abstract][Full Text] [Related]
12. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
[TBL] [Abstract][Full Text] [Related]
13. Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.
Smeenk L; Fischer M; Jurado S; Jaritz M; Azaryan A; Werner B; Roth M; Zuber J; Stanulla M; den Boer ML; Mullighan CG; Strehl S; Busslinger M
EMBO J; 2017 Mar; 36(6):718-735. PubMed ID: 28219927
[TBL] [Abstract][Full Text] [Related]
14. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
Jamrog L; Chemin G; Fregona V; Coster L; Pasquet M; Oudinet C; Rouquié N; Prade N; Lagarde S; Cresson C; Hébrard S; Nguyen Huu NS; Bousquet M; Quelen C; Brousset P; Mancini SJC; Delabesse E; Khamlichi AA; Gerby B; Broccardo C
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10357-10362. PubMed ID: 30257940
[No Abstract] [Full Text] [Related]
15. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML.
Kurahashi S; Hayakawa F; Miyata Y; Yasuda T; Minami Y; Tsuzuki S; Abe A; Naoe T
Oncogene; 2011 Apr; 30(15):1822-30. PubMed ID: 21217775
[TBL] [Abstract][Full Text] [Related]
16. A novel PAX5 rearrangement in TCF3-PBX1 acute lymphoblastic leukemia: a case report.
Barbosa TC; Lopes BA; Blunck CB; Mansur MB; Deyl AVS; Emerenciano M; Pombo-de-Oliveira MS
BMC Med Genomics; 2018 Dec; 11(1):122. PubMed ID: 30563523
[TBL] [Abstract][Full Text] [Related]
17. A patient with B-cell acute lymphoblastic leukemia with PAX5-ETV6 rearrangement with dic(9;12)(p13;p13) identified by chromosomal microarray.
Ha J; Kim B; Hahn S; Lee ST; Lyu CJ; Choi JR
Ann Hematol; 2018 Aug; 97(8):1505-1507. PubMed ID: 29520434
[No Abstract] [Full Text] [Related]
18. Locus-specific ChIP combined with NGS analysis reveals genomic regulatory regions that physically interact with the Pax5 promoter in a chicken B cell line.
Fujita T; Kitaura F; Yuno M; Suzuki Y; Sugano S; Fujii H
DNA Res; 2017 Oct; 24(5):537-548. PubMed ID: 28586432
[TBL] [Abstract][Full Text] [Related]
19. Modeling the molecular consequences of unbalanced translocations in cancer: lessons from acute lymphoblastic leukemia.
Strefford JC; An Q; Harrison CJ
Cell Cycle; 2009 Jul; 8(14):2175-84. PubMed ID: 19556891
[TBL] [Abstract][Full Text] [Related]
20. The PAX5-JAK2 translocation acts as dual-hit mutation that promotes aggressive B-cell leukemia via nuclear STAT5 activation.
Jurado S; Fedl AS; Jaritz M; Kostanova-Poliakova D; Malin SG; Mullighan CG; Strehl S; Fischer M; Busslinger M
EMBO J; 2022 Apr; 41(7):e108397. PubMed ID: 35156727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
